AMRX

Amneal Pharmaceuticals (AMRX) reported Q3 2026 earnings of $0.26 per share, beating consensus estimates of $0.24, with revenues of $862.68 million exceeding expectations by 5.44%. The company has outperformed the market by 62.2% year-to-date.

With a favorable estimate revision trend, AMRX received a Zacks Rank #2 (Buy) rating and is expected to outperform the market in the near term. The Medical - Drugs industry ranks in the top 35% of Zacks industries.

Amneal Pharmaceuticals is expected to report Q3 2026 earnings of $0.24 per share (up 41.2% YoY) with revenues of $818.22 million (up 4.3% YoY) on November 3. With a positive Earnings ESP of +4.17% and Zacks Rank #2 (Buy), the company is positioned as a likely earnings-beat candidate. The stock has beaten consensus estimates in all four of the last quarters.

Amneal Pharmaceuticals (AMRX) has demonstrated a consistent track record of beating earnings estimates, with an average surprise of 41.91% over the past two quarters. The company's positive Earnings ESP of +4.35% combined with its Zacks Rank #3 suggests another potential earnings beat ahead of its November 3, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time.